profit from every $100 of sales.
$0$100
Pharming Group
$12.60-2.70% today
-28.5% in 1 year
1-year low $9.111-year high $21.18
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $312.80 for every $1 of profit it makes in a year.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Pharming Group sold, what it kept, and what it did with the cash.
Sales went from $206 million in 2022 to $376 million in 2025, with $2.85 million of profit last year.
SalesProfit
Pharming Group vs. similar companies
Pharming Group grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pharming Group | 312.8× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Pharming Group's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 206 | 245 | 297 | 376 | |
| 188 | 220 | 262 | 331 | |
| 10 | -22 | -4 | 21 | |
| 34 | 10 | 16 | 35 | |
| 14 | -11 | -12 | 3 | |
| 0.19 | -0.15 | -0.16 | 0.04 | |
| 91.5% | 89.7% | 88.1% | 87.9% | |
| 4.8% | -9.1% | -1.2% | 5.6% | |
| 6.7% | -4.3% | -4.0% | 0.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 426 | 463 | 400 | 500 |
| Cash | 207 | 62 | 55 | 145 |
| Total debt | 167 | 172 | 112 | 116 |
| Total liabilities | 221 | 244 | 179 | 223 |
| 205 | 219 | 221 | 277 | |
| 72 | 67 | 69 | 71 | |
| 4.3% | -1.2% | 0.1% | 4.7% | |
| 6.7% | -4.8% | -5.4% | 1.0% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 22 | -17 | -2 | 55 | |
| 2 | 1 | 1 | 1 | |
| 20 | -19 | -3 | 54 | |
| Dividends paid | 0 | 0 | 0 | 0 |
| – | – | – | – | |
| 6 | 9 | 11 | 14 |
Valuation
- 312.8×
- 101.0×
- –
- 3.1×
- 2.4×
- 16.5×
- 24.8×
- 6.0%
- 0.3%
- 0.0%
Profitability
- 87.9%
- 5.6%
- 0.8%
- 9.1%
- 4.9%
- 2.0%
- 4.7%
- 2.5%
- 6.2%
- 28.3%
Growth
- +22.3%
- −40.5%
- +2,003.3%
- –
- −0.3%
Financial health
- -0.8×
- 0.42
- 23.7%
- 2.2×
- 2.59
- 2.06
- 0.76
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 46%of 952
Bottom 38%of 884
Bottom 1%of 601
Top 25%of 886
Top 17%of 987
What analysts expect
- Average price target
- $38.67
- Range
- $37.00 – $42.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.07 | 0.05 | −240.0% |
| Mar 12, 2026 | 0.07 | 0.15 | −53.3% |
| Nov 6, 2025 | 0.10 | 0.05 | +100.0% |
| Jul 31, 2025 | 0.06 | -0.10 | +160.0% |
| May 8, 2025 | -0.22 | -0.25 | +12.0% |
| Mar 13, 2025 | 0.05 | 0.07 | −28.6% |
| Oct 24, 2024 | -0.02 | 0.01 | −300.0% |
| Aug 1, 2024 | -0.01 | -0.00 | −400.0% |
News
Pharming reports Q3 revenueSeeking Alpha · Oct 22, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
44No pass
Benjamin Graham
36No pass
Philip Fisher
49No pass
Peter Lynch
39No pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
41No pass
Questions about Pharming Group
Is Pharming Group a good stock to buy?
A business with weak numbers, priced as if everything goes right. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pharming Group AI analysis
What does Pharming Group do?
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. It is in Biotechnology.
Does Pharming Group pay a dividend?
No. Pharming Group does not pay a dividend at the moment.
Is Pharming Group stock halal?
Yes. Pharming Group passes our halal screen: its business is permitted and its debt is 13% of its market value, under the 30% limit. How we check
How has Pharming Group stock done over the past year?
Down 28.5% over the past twelve months, to $12.60. It traded between $9.11 and $21.18 and is 40.5% below its high.
Who are Pharming Group's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Pharming Group's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.